Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the likelihood of antigen loss, thus improving sustained remission rates. A systematic approach to the gen...
Alternative Titles
Full title
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6300726
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6300726
Other Identifiers
ISSN
2372-7705
E-ISSN
2372-7705
DOI
10.1016/j.omto.2018.10.006
